Search

Keep up to date with the latest news, innovations, and developments, spotlighting groundbreaking research and emerging players.

Stay informed on the latest financial trends and investment opportunities, from startups to established players.

Explore the intersection of psychedelic medicine and cultural values, diving into ethical considerations and societal impacts within this transformative field.

Navigate the complex legal and political landscape surrounding psychedelic medicine, including regulatory updates, policy changes, and advocacy efforts.

Delve into cutting-edge scientific research and breakthroughs in the field of psychedelic medicine, with a focus on understanding the mechanisms, efficacy, and safety of these substances.

Discover the therapeutic potential of psychedelic substances, examining their role in mental health, personal growth, and overall well-being.

Nov 9-11, 2023 | Miami, FL

The Premier Global Event for Psychedelics, Mental Health & Longevity

Delve into the captivating world of psychedelic medicine at Wonderland, where the frontiers of science, spirituality, and wellness converge to create an experience unlike any other.

Discover the keys to living longer while exploring the potential of humanity’s future. Wonderland brings together the latest groundbreaking research, charting trends, and investment opportunities for an experience of a lifetime.

Uncover state-of-the-art technology, evolving trends, insightful marketing strategies, and valuable opportunities designed for professionals in the mental health and brain care sector.

With this year’s Wonderland, we want to expand the conversation to take a deep dive into the intersection of these fields with psychedelic medicine, and how combining all three can lead to living not only a longer, but happier life.

The premier global conference, Wonderland is a groundbreaking event experience where visionaries and pioneers unite to explore the future of psychedelic medicine, the business of mental health and the future of longevity medicine.

Are you ready to share your passion, knowledge, and insights with a global audience of executives, researchers, and practitioners? This is your opportunity to contribute to the evolving conversation on the future of medicine showcase your unique expertise, and inspire change in the world.

Wonderland presents a one-of-a-kind opportunity for businesses and organizations to exhibit their cutting-edge products, services, and visionary solutions to a captivated audience of professionals in the mental health and psychedelic medicine fields.

We invite companies with a shared vision to submit partnership proposals and collaborate with us on this extraordinary event. By joining forces, we can create a truly unique experience for attendees, foster lasting connections, and drive the future of psychedelic healing together.

Elevate your brand’s presence in the psychedelic medicine industry with our comprehensive suite of services, tailored to captivate your audience, strengthen your market position, and foster meaningful connections within the community.

Our website provides a platform for a range of custom content, putting your message in front of the industry’s most engaged and informed audience.

Our advertising options give you the ability to target users on their desktops, mobile devices, or when they’re at one of our in-person events. You decide when and where to connect with our audience.

Our dedicated team provides passion and specialist insight across a variety of sectors and services so, whatever the challenge, the impact is guaranteed.

You’re doing the hard work of changing the world, let our team of internationally award-winning creators focus on spreading the word as far as possible and telling your story to the world.

Microdose’s events and conferences are bringing psychedelic medicine to the mainstream. Top investors, business leaders, researchers, and advocates — our events are the hub for the psychedelic renaissance.

Justin Hanka
MindBio Therapeutics

The team at Microdose are leaders in public relations activities and have successfully assisted MindBio Therapeutics to reach a global audience that we would not have been able to reach without them.

Natalie Dolphin
Wellbeing Digital Science

The Microdose team worked with us, identifying key activities we were undertaking and promoting them through its wide-ranging media connections within psychedelics, cannabis and biotech publications. The Microdose team is professional and passionate about what it does, and this was reinforced during the pandemic when it went above and beyond our agreed contract, working with us to get key messages out to the industry quickly and effectively.

Microdose X is shifting the world’s perception of psychedelic medicine, one city at a time. Join the world’s fastest-growing psychedelic network and enjoy vibrant local meetups with like-minded souls.

The Science of Psychedelics is an accredited, definitive guide to the clinical applications of entheogenic medicines, and offers a solid introduction to psychedelic-assisted therapy and “trip sitting” skills to physicians, psychologists, social workers, mental health counselors, pharmacists, and other empowered individuals. Become trained in psychedelic medicines like psilocybin, LSD, MDMA, and ketamine today.

Psychedelia is a quarterly publication examining the ever-changing realm of drug policy and efforts to bring psychedelic therapies into the mainstream. From psilocybin mushrooms to LSD to DMT, psychedelics have the potential to revolutionize mental healthcare in North America. Psychedelia will detail the journey towards acceptance of psychedelic-assisted therapies.

Microdose is a small team of people who want to help share the potential of psychedelic medicine with the world, bringing together our unique expertise and diverse backgrounds to create a platform that inspires, informs, and fosters a thriving community in this transformative field.

Our team shares a passion for psychedelic medicine and we all have a different story on how we ended up here. We want to share those stories and highlight the amazing people that help us do what we do.

Connect with our team to explore how we can collaborate and unlock the potential of psychedelic medicine together, fostering growth and innovation in this dynamic industry.

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

Health & Wellness

28 Feb 2024

Integrating Psychedelic Experiences for Mental Health: The Importance of Aftercare

Psychedelics have been shown to have several potential benefits for mental health, including reducing anxiety, depression, and post-traumatic stress disorder (PTSD). However, for these benefits to be realized, it is important to integrate the psychedelic experience into one's life after the session has ended. This is known as “integration” or "aftercare."

BY Microdose NewsDesk

MindBio Therapeutics has announced groundbreaking results from a Phase 2a clinical trial involving the take-home microdosing of MB22001 for treating depression. This world-first trial showcased a significant decrease in depression symptoms over 8 weeks, with a 60% reduction in depressive symptoms and 53% of patients achieving complete remission.
Microdose takes a look back at some of the top psychedelic stories of 2023.
We take a deeper look at ancient shamanic traditions, exploring how magic mushrooms may be a part of Christmas history.
Terran Biosciences Receives FDA Clearance for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2A Take-Home Microdosing Trial
MindBio Therapeutics has announced groundbreaking results from a Phase 2a clinical trial involving the...
Breaking News: MAPS Files New Drug Application With FDA for MDMA-Assisted Therapy
Historic filing marks first New Drug Application submission for any psychedelic-assisted therapy.
Terran Biosciences Granted Four Patents for New Forms of Psychedelics
Terran’s new patents cover new psilocybin forms, orally active DMT, and 5-MeO-DMT, and novel forms of...
Cybin Reports Positive Topline Data from Phase 2 Study of Major Depressive Disorder
Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed...
Cybin Announces Positive Phase 2 Data for Phase 2 Depression Trial
This morning we received interim results on Cybin’s Phase 2 trial using its CYB003 psilocybin compound...
Breaking News: Beckley Waves Acquires Nue Life
In breaking news, Beckley Waves announces the acquisition of Nue Life.
Breaking News: California Governor Vetoes Psychedelics Decriminalization Bill
California governor has vetoed a major psychedelic decrim bill, but supports a comprehensive law that...
PharmaTher Submits New Drug Application to the FDA
Will PharmaTher be the next company to get a psychedelic medicine to market?
Breaking News: Otsuka Pharmaceutical to Acquire Mindset Pharma
This morning we received news of Mindset Pharma being sold to a big pharma player, Otsuka Pharmaceutical. 
Breaking News: Cybin to Acquire Small Pharma
In big breaking news, Cybin has signed a deal to acquire Small Pharma, giving Cybin an advanced DMT trial.

Purchase Dissolve Now by Paul Nolan

The inaugural album from Microdose Music is out now. Each track is meticulously crafted, and designed to elicit specific emotional responses, elevate mood, and unlock hidden potential within the listener.

[stock_market_widget type="ticker-quotes" template="chart" color="#0F4C81" assets="ATAI,CYBN,ABRT.CN,LSDI,MDMA.CN,CMPS,REUN,AWKNF,VEGGD,BETRF,BMND.NE,BRAX.CN,DRUG,CMND,COOL.CN,ENBI.CN,ENVB,FTHWF,FLHLF,GHRS,PSYC,HAVLF,IXHL,IWINF,LOBEF,MNMD,MSET.CN,MYCOF,NIRV.CN,NOVA.CN,NUMI.TO,OPTHF,KTTA,PHRX.CN,PHRM.CN,PSYB.V,PSYC.CN,PSYG.CN,PULL.CN,TRIP.CN,CALM.CN,RVV.CN,SEEL,SILO,DMT.V,MUSH.V,THRN,PEMTF,TSTTF,TRYP.CN,IBO.V,MEDI.NE,WESA.CN" animation="true" display_currency_symbol="true" api="yf" speed="200" direction="left" style="font-family: 'League Spartan'" pause="true"]
Johnson & Johnson has released its 3rd quarter results and once again Spravato sales have shown impressive growth.
Cybin shareholders approve the acquisition of Small Pharma with 99.4% of the vote.
Renowned billionaire investor Steve Cohen has purchased almost 19 million shares of Cybin.
Johnson & Johnson has released its 3rd quarter results and once again Spravato sales have shown impressive growth.
Cybin shareholders approve the acquisition of Small Pharma with 99.4% of the vote.
Renowned billionaire investor Steve Cohen has purchased almost 19 million shares of Cybin.
Beckley Waves raises $3.3 million, capital to be used for investing in startups focused on infrastructure and services for psychedelic therapies.
GH Research has reported its second quarter 2023 financial results, with updates on trials and cash on hand.
MindMed secures $50 Million credit facility with K2 HealthVentures, giving company access to additional capital
Beckley Waves raises $3.3 million, capital to be used for investing in startups focused on infrastructure and services for psychedelic therapies.
GH Research has reported its second quarter 2023 financial results, with updates on trials and cash on hand.
MindMed secures $50 Million credit facility with K2 HealthVentures, giving company access to additional capital

Explore the Psychedelic Universe

Discover companies working in psychedelic medicine, find jobs in the industry, and explore qualified candidates looking for work.
The Endocannabinoid System in Palliative Care
Palliative care is a cornerstone of healthcare, aiming to augment the quality of life for patients grappling...
Santa's Trippy Origins: Exploring the Psychedelic Roots of Christmas
We take a deeper look at ancient shamanic traditions, exploring how magic mushrooms may be a part of...
Wonderland and Kandyflip.Art Present Art Auction Featuring Rare Graffiti Art From Renowned Artists
Wonderland and Kandyflip.Art Present Art Auction Featuring Rare Graffiti Art From Renowned Artists

This industry wouldn't be anything without the community of supporters who have pushed for progression with psychedelic medicine. We want to share the stories of those who have been affected by psychedelics.

SUBSCRIBE TO OUR NEWSLETTER

PsychedelicsOne

The only newsletter you'll need in psychedelics.

Law & Politics

9 Dec 2023

US Congress Adds Psychedelics Studies to Defense Bill

A bipartisan group of congressional lawmakers from both the House and the Senate have added funding for studies of psychedelic therapies into a major defense bill.

BY Jason Najum

Law & Politics

20 Oct 2023

Eureka! California City Approves Psychedelic Decriminalization

Eureka, California has become the latest city to decriminalize psychedelic medicines.

BY Jason Najum

Breaking News, Law & Politics

8 Oct 2023

Breaking News: California Governor Vetoes Psychedelics Decriminalization Bill

California governor has vetoed a major psychedelic decrim bill, but supports a comprehensive law that establishes guidelines for regulated therapeutic access.

BY Jason Najum

california mushroom

Law & Politics

5 Oct 2023

California Passes Bill Allowing Doctors to Prescribe Psychedelics If Federally Re-Scheduled

California Governor Gavin Newsom has signed a bill that allows doctors to legally prescribe psychedelics when re-scheduled by the federal government.

BY Microdose NewsDesk

Law & Politics

29 Sep 2023

Canadian Military Veteran Receives Approval for Psilocybin Therapy

Health Canada has granted permission for a Canadian military veteran to receive much-needed psilocybin therapy.

BY Jason Najum

decrim

Law & Politics

7 Sep 2023

California Assembly Approves Psychedelics Legalization Bill

California is reaching the final stages of psychedelic legalization, as the California State Assembly passes a bill permitting the possession of certain psychedelics.

BY Microdose NewsDesk

Exploring the Business and Culture of Psychedelics

Psychedelia is a quarterly publication examining the ever-changing realm of drug policy and efforts to bring psychedelic therapies into the mainstream. From psilocybin mushrooms to LSD to DMT, psychedelics have the potential to revolutionize mental healthcare in North America. Psychedelia will detail the journey towards acceptance of psychedelic-assisted therapies.

A new study looks at emotionally painful, shame-related processes with psychedelic use.
The FDA has issued a warning letter regarding the use of ketamine outside of FDA-approved conditions.
A new study in rodents shows that low doses of psilocybin increase resilience to stress and lower compulsive actions.
A new study published in the New England Journal of Medicine found that Spravato’s esketamine was more effective than a commonly prescribed drug in treating treatment-resistant depression.
Topline results from Small Pharma's Phase Ib study exploring the interaction between SSRIs and SPL026, the company’s DMT drug.

The Science of Psychedelics

Professional Training for Psychedelic Medicine

Self-Directed Training for Psilocybin, LSD, MDMA, and More

featured-image-blog
Psychedelics have been shown to have several potential...
therapy
Psychedelics can be powerful tools for healing. But...
Compress_20230816_162243_3281
Addiction is a challenging condition that affects millions...
Compress_20230811_114457_7972
A look at the research on microdosing psychedelics...
age brain
As the population ages, there is a growing interest...

Industry

20 Sep 2023

Numinus Closes Bioscience Lab and Consolidates Clinics

Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations.

BY Microdose NewsDesk

Science

19 Sep 2023

New Johns Hopkins’ Study Shows Psilocybin Promotes Mental Health Improvements

A new study published by researchers from Johns Hopkins shows that psilocybin produces lasting improvements in mental health symptoms and general well-being.

BY Microdose NewsDesk

maps

Industry

14 Sep 2023

MAPS Publishes Results of Successful Phase 3 Trial

In big industry news, MAPS has published the second part of its long-awaited Phase 3 trial of MDMA-assisted therapy for PTSD.

BY Microdose NewsDesk

Mindmed trial

Industry

12 Sep 2023

MindMed Completes Dosing of Phase 2b Trial

MindMed has completed dosing of its main Phase 2b clinical trial. The study — investigating LSD for Generalized Anxiety Disorder (GAD) — has dosed 198 participants across 20 clinical sites.

BY Microdose NewsDesk

Industry

11 Sep 2023

PurMinds Appoints Leading Drug Designer to Scientific Advisory Board

Dr. Kozikowski is a leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience.

BY Microdose NewsDesk

concordia

Industry

8 Sep 2023

Microdose Partners with Concordia for 2023 Annual Summit in New York City

Microdose is partnering with Concordia for the 2023 Concordia Annual Summit, taking place September 18-20 in New York City.

BY Microdose NewsDesk

Awakn Life Sciences has submitted a Clinical Trial Application for a phase III trial for its lead program for the treatment of Severe Alcohol Use Disorder.
candy flipping

Science

7 Sep 2023

New Study Shows Candy-Flipping Can Reduce Bad Trips

A new study published in Nature shows that MDMA can reduce difficult experiences with other psychedelics.

BY Microdose NewsDesk

ketamine

Breaking News

6 Sep 2023

PharmaTher Submits New Drug Application to the FDA

Will PharmaTher be the next company to get a psychedelic medicine to market?

BY Jason Najum

Culture

6 Sep 2023

Ethical Concerns in Psychedelic Therapy

A deeper look at some of the ethical concerns in the psychedelic medicine space and how to best address them. 

BY Microdose

The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine (5-MeO-DMT) analogs.

Science

1 Sep 2023

Usona Publishes Results of Phase 2 Psilocybin Trial for Depression

Results of the Usona Institute’s Phase 2 trial using psilocybin for depression were published yesterday.

BY Microdose NewsDesk

mushroom deal

Breaking News

31 Aug 2023

Breaking News: Otsuka Pharmaceutical to Acquire Mindset Pharma

This morning we received news of Mindset Pharma being sold to a big pharma player, Otsuka Pharmaceutical. 

BY Microdose NewsDesk

mushrooms

Science

31 Aug 2023

New Johns Hopkins Study Shows Psilocybin Helps Long Term Mental Health

A new study from Johns Hopkins shows that psilocybin use promotes positive long-term effects on well-being.

BY Jason Najum

Breaking News

28 Aug 2023

Breaking News: Cybin to Acquire Small Pharma

In big breaking news, Cybin has signed a deal to acquire Small Pharma, giving Cybin an advanced DMT trial.

BY Microdose NewsDesk

Industry

28 Aug 2023

Using Virtual Reality for Innovation and Safer Psychedelic Experiences

VR can be used to help prepare for psychedelic therapy, guide them through the journey, and help them integrate experiences.

BY Microdose

Culture

25 Aug 2023

Harm Reduction at Psychedelic Gatherings: Best Practices and Strategies

Harm reduction measures and other safety strategies are crucial for positive and responsible experiences. We take a closer look.

BY Microdose

Culture

24 Aug 2023

Breaking Down Barriers: Creating Inclusive Psychedelic Communities

Exploring challenges and strategies to increase accessibility and diversity in the psychedelic therapy space.

BY Microdose

Health & Wellness

23 Aug 2023

Psychedelics and Addiction: How Substances Like Ibogaine Are Revolutionizing Treatment Options

Addiction is a challenging condition that affects millions of individuals worldwide. Substances like Ibogaine can facilitate profound healing and recovery.

BY Microdose

psychedelic mushrooms

Culture

22 Aug 2023

The Intersection of Psychedelic Culture, the Environment, and Sustainability

BY Microdose

A deeper look at how psychedelic art communicates individual experiences and contributes to culture.

Health & Wellness

18 Aug 2023

Microdosing for Longevity: A Tool for Healthy Aging?

A look at the research on microdosing psychedelics and how it may help mental health and longevity.

BY Microdose

Culture

17 Aug 2023

Breaking the Stigma: How Psychedelic Advocacy is Changing Public Perception

Advocates are working to educate the public on the benefits of psychedelics, helping to dispel myths and increase access.

BY Microdose

mushrooms

Breaking News

16 Aug 2023

COMPASS Pathways Announces Capital Raise of Up to $285 Million

COMPASS Pathways has announced a capital raise of up to $285 million, the largest cash injection the industry has seen in quite some time.

BY Microdose NewsDesk

We explore the aspects of a holistic psychedelic lifestyle, including integration work, ongoing education, self-care, and community involvement.

Industry

15 Aug 2023

Cybin Granted U.S. Patent For Psilocybin Program

Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041

BY Microdose NewsDesk

Culture

15 Aug 2023

Psychedelic Tourism: A Look at Ethics, Sustainability, and Safety

Exploring psychedelic tourism, with a focus on ethical considerations, sustainability, and strategies to ensure safety and respect for indigenous practices.

BY Microdose

Finance

15 Aug 2023

Cybin Reports Q1 Financial Results and Business Highlights

Cybin reports first quarter financial results and business highlights, including updates on key trials.

BY Microdose

We explore the history and cultural influence of psychedelic festivals, with a look at safety and harm-reduction practices within these transformative events.

Science

11 Aug 2023

New Study Compares Psychedelics to Hypnosis and Meditation

A new study explores what happens in the brain while under the influence of psychedelics, meditation, and hypnosis.

BY Jason Najum

Health & Wellness

11 Aug 2023

Promoting Healthy Aging: Can Psychedelic Therapy Enhance Quality of Life in Seniors?

BY Microdose

Breaking News

10 Aug 2023

Christian Angermayer Gives Insight on Future of Atai’s Ketamine Program

Christain Angermayer gave some clarification on PCN-101, atai's ketamine program, hinting at new direction for the compound.

BY Jason Najum

Industry

10 Aug 2023

First Professional Practice Guidelines Published for Psychedelic-Assisted Therapy

The American Psychedelic Practitioners Association (APPA) has released the first-ever set of professional practice guidelines for psychedelic-assisted therapy.

BY Microdose NewsDesk

Health & Wellness

10 Aug 2023

Creating Safe Spaces: The Role of Psychedelic Integration Circles

It's important to use psychedelics in a safe and supportive environment. This is where psychedelic integration comes in.

BY Microdose

Breaking News, Industry

9 Aug 2023

atai Life Sciences Announces Results of New Phase 1 Study of PCN-101 (R-Ketamine)

Atai announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine).

BY Microdose NewsDesk

Health & Wellness

9 Aug 2023

Psychedelic-Assisted Therapy: Expanding Access and Ensuring Safety

it's important to ensure that psychedelic therapy is accessible to those who need it and is conducted in a safe and ethical manner.

BY Microdose

Industry

8 Aug 2023

Filament Health Announces FDA Approval of Two Clinical Trials

FDA has approved two clinical trials studying the effects of PEX010, Filament's botanical psilocybin drug candidate.

BY Microdose NewsDesk

Industry

8 Aug 2023

Algernon NeuroScience Announces Phase 2 DMT Stroke Study

Algernon NeuroScience has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.

BY Microdose NewsDesk

Culture

8 Aug 2023

The Intersection of Psychedelic Medicine and Traditional Healing Practices

Can the modern psychedelic medicine movement learn from traditional healing practices?

BY Microdose

Culture

6 Aug 2023

Exploring the Role of Music in Psychedelic Therapy and Culture

We take a look at how music can not only enhance the psychedelic experience but lead to better and more profound therapeutic outcomes.

BY Microdose

Finance

4 Aug 2023

MindMed Reports Second Quarter 2023 Financial Results and Highlights

MindMed released its Q3 financial results. Highlights include enrolment in Phase 2b LSD trial, top-line results by end-of-year, and $116 million in cash.

BY Microdose NewsDesk

Industry

4 Aug 2023

Affordable Ketamine Treatments: Interview With Dr. Bryan Henry of PsychMD

We sat down with PsychMD founder Bryan Henry to discuss the company’s ambitious roll-out and focus on affordable ketamine treatments.

BY Microdose

Industry

3 Aug 2023

Psyence Announces SEC Registration For NASDAQ (by SPAC Merger)

Psyence announces a SPAC merger and filing with the SEC for eventual NASDAQ trading.

BY Microdose NewsDesk

Health & Wellness

3 Aug 2023

Deeper Healing: An Introduction to Psychedelic Integration

We explore integration in a psychedelic therapy setting and how it can enhance the therapeutic process.

BY Microdose

Industry

2 Aug 2023

Awakn Life Sciences Completes Sale of Clinics; Shifts To Biotech Development

Awakn Life Sciences has sold its last clinic and shifted its focus entirely to its clinical trials and biotech research.

BY Jason Najum

Culture

2 Aug 2023

Barriers to Accessing Psychedelic Medicine: Exploring Solutions

Psychedelic medicine is making enormous strides. But many barriers still exist that hinder individuals from accessing psychedelic therapy.

BY Microdose

Breaking News, Finance

1 Aug 2023

Raising Capital: Cybin Announces Public Offering

Cybin has announced a public offering for gross proceeds of US$8,250,000.

BY Microdose NewsDesk

Culture

1 Aug 2023

Psychedelic Culture: Past, Present, and Future

Psychedelic culture has a long and rich history. It has influenced music, art, and spirituality in profound ways. We take a closer look.

BY Microdose

Law & Politics

28 Jul 2023

House Approves Psychedelics Research Amendments in Major Spending Bill

A bi-partisan amendment to promote research into psychedelics has passed a vote in the U.S. House of Representatives.

BY Microdose NewsDesk

Industry

27 Jul 2023

Rexis Biotech: Improving Functional Ingredients With Innovative Technology

Rexis Biotech is using new technology to change how we produce and consume consumer ingredients.

BY Microdose

Industry

26 Jul 2023

EXCLUSIVE: Interview with Terran Biosciences founder Sam Clark

See Microdose's exclusive Q&A with Terran’s founder and CEO to learn more about the company and their recent discoveries.

BY Microdose NewsDesk

Industry

26 Jul 2023

Wonderland Expands: Bringing Together Psychedelics, Mental Health, & Longevity

Microdose’s Wonderland conference is the premier industry event in the psychedelic medicine space - and now it's expanding into mental health and longevity.

BY Jason Najum

Industry

25 Jul 2023

Positive Results Published for Compass Pathways’ COMP360 For Anorexia

A study using Compass Pathways’ COMP360 psilocybin compound for anorexia was published in Nature Medicine.

BY Jason Najum

Industry

24 Jul 2023

Cybin Announces Phase 2 Dosing Completion of CYB003 Trial (Cohort 5)

Cybin announces Phase 2 cohort 5 dosing completion of CYB003 in Major Depressive Disorder

BY Microdose NewsDesk

Law & Politics

24 Jul 2023

Minneapolis Mayor Signs Order Making Psychedelics ‘Lowest Law Enforcement Priority’

The mayor of Minneapolis signed an executive order making the criminalization of psychedelics the city’s lowest law enforcement priority.

BY Microdose NewsDesk

Industry

21 Jul 2023

Bright Minds Biosciences Announces Positive Data for Phase 1 Study of BMB-101

Bright Minds Biosciences announced the successful completion of its three-part Phase 1 study of BMB-101

BY Microdose NewsDesk

Breaking News

20 Jul 2023

Filament Health Heading to NASDAQ With SPAC Merger

The agreement would merge Filament with Jupiter Acquisition Corporation (NASDAQ: JAQC)

BY Microdose NewsDesk

Science

20 Jul 2023

New Study Shows Ketamine Effective Against Treatment-Resistant Depression

Results from a phase 3 trial show that generic ketamine was safe and effective in treating patients with treatment-resistant depression.

BY Microdose NewsDesk

DMT

Industry

19 Jul 2023

PharmaTher Announces Positive Research Results for DMT and Investment into Sairiyo Therapeutics

PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

BY Microdose NewsDesk

Culture

19 Jul 2023

The World’s First Functional Music Record Label: An Interview With Paul Nolan

Microdose Music and Paul Nolan are launching a new psychedelic album and functional music record label.

BY Jason Najum

Industry

18 Jul 2023

First Salts And Polymorphs of 4-OH-DiPT Discovered by Terran Biosciences; Patent Application Filed

A PCT patent application from Terran Biosciences was just published covering their discovery of novel salts and polymorphs of the compound 4-OH-DiPT.

BY Microdose NewsDesk